Clinical Trial Current Events | Clinical Trial News | 9
|
| Page
9 of
57 |
1140 Results |
|
|
|
Sort By:
Page Views | Date |
Image-guided treatment for deep venous thrombosis could improve patients' long-term outcomes
Deep Venous Thrombosis (DVT) is a serious condition that involves the formation of a blood clot inside of a deep vein usually in the legs. A patient with DVT is typically treated with anticoagulants (blood thinners) however researchers have found that image-guided interventional radiology procedures may play a more central role in the long-term... view more... (2009-09-21)
2-drug combination appears safe and active in metastatic kidney cancer
Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. view more (2009-06-01)
Health of independent clinical trials in danger, scientist warns
European Union legislation due to take effect next year could have a disastrous effect on non-commercial clinical trials, said a leading cancer researcher today. Speaking at ECCO 12 - The European Cancer Conference in Copenhagen, Professor Fran'§oise Meunier, Director General of the EORTC1 Brussels, Belgium, told a news briefing that the new... view more... (2003-09-22)
New therapy enlists immune system to boost cure rate in a childhood cancer
A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the nervous system. view more (2009-05-28)
Scientists design a PSA-activated protoxin that kills prostate cancer
Scientists have found a way of using a protein made by prostate cancer to target and kill the cancer cells themselves. In preliminary studies the new therapy affected only the prostate, without causing damage to other healthy tissues, and now it is being tested in a phase I clinical trial. view more (2006-11-10)
Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer
A cancer-suppressing gene has been successfully delivered into the tumors of stage 4 lung cancer patients via an intravenously administered lipid nanoparticle in a phase I clinical trial at The University of Texas M. D. Anderson Cancer Center. view more (2007-04-18)
Sorafenib significantly improves the length of time before breast cancer worsens
ne of the first of a series of trials to investigate the use of sorafenib - a targeted anti-cancer drug - for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening. view more (2009-09-23)
Unique nerve-stimulation device proves effective against epilepsy
Epilepsy is a common medical condition characterized by convulsions and short periods of confusion. It affects more than 50 million people worldwide. But intractable epilepsy, which affects more than 1 million Americans and is often resistant to drug treatment and surgery, is arguably worse. view more (2009-03-19)
Low-fat diet possibly linked to lower risk of ovarian cancer
A low-fat diet may decrease the risk of ovarian cancer in postmenopausal women. view more (2007-10-10)
New treatment shows promise against recurrent gynecologic cancers
Recurrent and metastatic endometrial and ovarian cancers can be notoriously difficult to treat: They have spread to other organs and typically have developed resistance to chemotherapy; and patients already heavily treated with chemotherapy may not be able to endure more chemo. view more (2009-04-22)
Clinical study results using Aldagen's product to isolate cord blood stem cells presented at ASH
Aldagen, Inc. today announced the presentation of data from a clinical trial using its ALDESORT® product to isolate stem cells from cord blood. The trial is being conducted by Joanne Kurtzberg, MD, the Duke University physician who pioneered the use of umbilical cord blood as a treatment for fatal childhood cancers and genetic diseases in... view more... (2006-12-12)
Press conference invitation: major new findings on smoking, smoking cessation and lung cancer
DATE: Wednesday 2nd August 2000 TIME: 10.15am for 10.30am VENUE: Room C, BMA House, Tavistock Square, London, WC1H 9JP CHAIRMAN: Dr Richard Smith, Editor, British Medical Journal SPEAKERS: Professor Sir Richard Peto, Co-Director of Imperial Cancer Research Fund... view more... (2000-08-01)
Can an over-the-counter vitamin-like substance slow the progression of Parkinson's disease?
Rush University Medical Center is participating in a large-scale, multi-center clinical trial in the U.S. and Canada to determine whether a vitamin-like substance, in high doses, can slow the progression of Parkinson's disease, a neurodegenerative disorder that affects about one million people in the United States. view more (2009-09-22)
Study shows combination of immune substances to be safe
New research has shown that the immune-stimulating hormone known as interleukin-12 (IL-12) can safely be administered with interferon, another immune-system protein, as an experimental therapy for some cancers. view more (2005-12-12)
Impact of fondaparinux tested on most serious heart attacks
The results of a large international cardiovascular trial will shed light on whether the addition of a new drug that prevents blood clotting, or thrombosis, can improve the treatment of the most serious form of heart attacks. view more (2006-03-15)
Coronary imaging techniques helps to identify plaques likely to cause heart attacks
Late-breaking results from the PROSPECT clinical trial shed new light on the types of vulnerable plaque that are most likely to cause sudden, unexpected adverse cardiac events, and on the ability to identify them through imaging techniques before they occur. view more (2009-09-25)
Fewer adverse cardiac events at one year
Late breaking results from the SPIRIT III trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that after 12 months, there were significantly fewer major adverse cardiac events (MACE) such as heart attacks, deaths from cardiac causes or repeat procedures (angioplasty or surgery) to clear the... view more... (2007-10-24)
Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapy
Non-small cell lung cancer patients who have progressed on a cetuximab-containing regimen may respond to erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer. view more (2009-08-03)
Vitamin B does not slow cognitive decline in Alzheimer's
A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease. view more (2008-10-15)
Combination of aspirin and an anti-clotting drug reduces risk of dialysis access failure
For the first time, a combination of aspirin and the anti-platelet drug dipyridamole has been shown to significantly reduce blockages and extend the useful life of new artery-vein access grafts used for hemodialysis, according to a study by the Dialysis Access Consortium (DAC). view more (2009-05-21)
|
|
| Page
9 of
57 |
1140 Results |
|
|
|
Sort By:
Page Views | Date |
|
